Optimizing Regimens and Managing Adverse Events in TIE NDMM

Elizabeth O’Donnell, MD, comments on specific patient subgroups, such as frail or high-risk individuals, who benefit most from particular regimens. She discusses adverse events observed in combination therapies for transplant-ineligible patients with newly diagnosed multiple myeloma and shares her approaches to managing these adverse effects in clinical practice.

EP: 1.Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP: 2.Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

EP: 3.Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

Now Viewing

EP: 4.Optimizing Regimens and Managing Adverse Events in TIE NDMM

EP: 5.Looking Ahead and Key Takeaways

EP: 6.Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP: 7.Overview of PERSEUS, IsKia, and GMMG-HD7

EP: 8.Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

1. Please comment on whether there are specific patient subgroups (eg, frail or high risk) that benefit most from one regimen over the other?
2. Please comment on some adverse events observed in combination therapies in transplant-ineligible patients with newly diagnosed multiple myeloma.

• Please address how you manage these adverse effects in clinical practice.

Related Videos